No profile data available.
Zevra Therapeutics, Inc. (ZVRA) is a healthcare company in the metabolic process treatment drugs industry, based in Boston, United States, with about 61 full-time employees.
It reported revenue of $23.61 million for fiscal year 2024, and net income of -$105.51 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $26.06 million, up 605.4% from a year before. Its market capitalization was $676.38 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Zevra Therapeutics reported $23.61 million in revenue for fiscal year 2024. In Q3 2025 revenue was $26.06 million.
$676.38 million as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include NewAmsterdam Pharma Company N.v. (NAMS), Disc Medicine, Inc. (IRON), Maze Therapeutics, Inc. (MAZE), Amarin Corporation plc (AMRN).